Extracorporeal photopheresis in acute and chronic steroid‑refractory graft-versus-host disease: an evolving treatment landscape

Patients with steroid-refractory graft-versus-host disease (GvHD) are known to have a poor prognosis and for decades no approved drug has been available to treat this serious condition. Although ruxolitinib, a selective Janus kinase (JAK)1/2 inhibitor demonstrated significantly higher response rates...

Descripción completa

Detalles Bibliográficos
Autores principales: Greinix, Hildegard T., Ayuk, Francis, Zeiser, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613461/
https://www.ncbi.nlm.nih.gov/pubmed/36153436
http://dx.doi.org/10.1038/s41375-022-01701-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613461/
https://www.ncbi.nlm.nih.gov/pubmed/36153436
http://dx.doi.org/10.1038/s41375-022-01701-2

Ejemplares similares